Hepatocellular Carcinoma (HCC)

TARGET-HCC is currently enrolling

TARGET-HCC

While there has been great progress in hepatocellular carcinoma research, there remains significant opportunity to better understand the disease in order to identify appropriate treatment strategies.  TARGET-HCC is collecting real world data to enhance the understanding of the natural history and management of HCC in the real world setting.  TARGET-HCC also has a biorepository linked to validated clinical outcomes, including patient reported outcomes. This offers partners a way to achieve better clinical outcomes and provide better care for patients.

Initial Goals include: 

  • Understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice
  • Evaluate the impact of HCC treatment interventions and concomitant medications on co-morbid conditions and liver function
  • Evaluate patient-reported outcomes measured during the natural course and management of HCC

Launched: September, 2016

Targeted number of patients: 5,000 

TARGET-HCC Steering Committee

Adrian Di Bisceglie, MD (co-Chair)
Chief of Hepatology and the Co-Director of the Saint Louis University Liver Center; Chairman of the Department of Internal Medicine; Professor of Internal Medicine

Anthony El-KhoueiryMD (co-Chair)
Associate Professor of Clinical Medicine at the University of Southern California Norris Comprehensive Cancer Center; Medical Director of Clinical Investigations Support Office and Phase 1 Program Director at USC Norris Comprehensive Cancer Center

Roniel Cabrera, MDMS (Protocol Author)
Associate Professor of Medicine, Division of Gastroenterology and Hepatology, University of Florida College of Medicine

Michael W. FriedMD (Scientific Advisor)  
Professor of Medicine and Director of Hepatology at the University of North Carolina at Chapel Hill

David Nelson, MD (Scientific Advisor)
Professor of Medicine and Assistant Vice President for Research at the University of Florida College; Director of the UF Clinical and Translational Science Institute

Bruno SangroMD 
Director of the Liver Unit and Professor of Internal Medicine at Clinica Universidad de Navarra

R.Kate (Katie) Kelley, MD 
Associate Professor of Clinical Medicine, Division of Hematology, Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center

Massimo Colombo, MD 
Head Centre for Translational Research in Hepatology. Humanitas Research, Rozzano, Italy

Tim MeyerMD 
Professor of Experimental Cancer Medicine and Consultant in Medical Oncology, Royal Free Hospital and UCL Cancer Institute, University College London